Imiquimod maleate (TMX101; R837; S26308; Zyclara; Aldara), the maleate salt of imiquimod, is an immune response modifier acting as an agonist of the TLR7 (toll-like receptor 7). Imiquimod has been approved to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. Scientists at 3M's pharmaceuticals division discovered the drug and 3M obtained the first FDA approval in 1997 under the brand name of Aldara. As of 2015, imiquimod is generic and is available worldwide under many brands. Imiquimod signals to the innate arm of the immune system through the TLR7, commonly involved in pathogen recognition. Cells activated by imiquimod via TLR-7 secrete cytokines such as interferon-α (INF-α), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Imiquimod has been studied in combination with pembrolizumab for treating stage IIIB-IV melanoma.

纯度：≥98%

CAS：896106-16-4